XNASKROS
Market cap665mUSD
Dec 27, Last price
16.42USD
1D
-2.32%
1Q
-70.91%
IPO
-23.88%
Name
Keros Therapeutics Inc
Chart & Performance
P/E
—
P/S
4,404.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.09%
Rev. gr., 5y
-56.77%
Revenues
151k
Net income
-153m
L+46.15%
CFO
-125m
L+77.71%
Earnings
Feb 26, 2025
Profile
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 151 | 20,100 | ||||
Cost of revenue | 170,907 | 116,405 | 77,371 | |||
Unusual Expense (Income) | ||||||
NOPBT | (170,756) | (116,405) | (57,271) | |||
NOPBT Margin | ||||||
Operating Taxes | 1,000 | 2,011 | ||||
Tax Rate | ||||||
NOPAT | (170,756) | (116,406) | (59,282) | |||
Net income | (152,992) 46.15% | (104,680) 78.20% | (58,744) 29.50% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 175,825 | 119,578 | 28,171 | |||
BB yield | -15.02% | -9.87% | -2.06% | |||
| Debt | ||||||
Debt current | 1,005 | 455 | 862 | |||
Long-term debt | 27,883 | 26,077 | 1,324 | |||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (303,471) | (253,843) | (229,183) | |||
| Cash flow | ||||||
Cash from operating activities | (124,508) | (70,062) | (62,148) | |||
CAPEX | (2,464) | (1,241) | (1,024) | |||
Cash from investing activities | (2,464) | (1,241) | (1,024) | |||
Cash from financing activities | 178,956 | 120,309 | 28,550 | |||
FCF | (172,655) | (121,159) | (70,496) | |||
| Balance | ||||||
Cash | 331,147 | 279,048 | 230,042 | |||
Long term investments | 1,212 | 1,327 | 1,327 | |||
Excess cash | 332,351 | 280,375 | 230,364 | |||
Stockholders' equity | (381,423) | (228,432) | (123,753) | |||
Invested Capital | 728,080 | 519,071 | 367,910 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 29,447 | 25,241 | 23,334 | |||
Price | 39.76 -17.20% | 48.02 -17.93% | 58.51 -17.05% | |||
Market cap | 1,170,817 -3.40% | 1,212,074 -11.22% | 1,365,267 24.82% | |||
EV | 867,346 | 958,231 | 1,136,084 | |||
EBITDA | (169,941) | (115,731) | (56,893) | |||
EV/EBITDA | ||||||
Interest | 1,000 | 4 | ||||
Interest/NOPBT | ||||||